All Stories

  1. Insights into the Pathogenesis of Anaplastic Large-Cell Lymphoma through Genome-wide DNA Methylation Profiling

    Article • Cell Reports, October 2016, Elsevier

    Dr Suzanne D Turner

  2. μ-Crystalline as hormone antagonist in prostate cancer

    Article • Endocrine Abstracts, September 2016, Bioscientifica

    Dr Suzanne D Turner

  3. Challenging perspectives on the cellular origins of lymphoma

    Article • Open Biology, September 2016, Royal Society Publishing

    Dr Suzanne D Turner

  4. Abstract 671: Assessing the origins of anaplastic large cell lymphoma in murine models via forced lineage specificity of NPM-ALK expression in T cells

    Article • Cancer Research, July 2016, American Association for Cancer Research (AACR)

    Dr Suzanne D Turner

  5. Anaplastic large cell lymphoma in paediatric and young adult patients

    Article • British Journal of Haematology, February 2016, Wiley

    Dr Suzanne D Turner

  6. Anaplastic large cell lymphoma arises in thymocytes and requires transient TCR expression for thymic egress

    Article • Nature Communications, January 2016, Nature

    Dr Suzanne D Turner

  7. Anti-ALK Antibodies in Patients with ALK-Positive Malignancies Not Expressing NPM-ALK

    Article • Journal of Cancer, January 2016, Ivyspring International Publisher

    Dr Suzanne D Turner

  8. Excess of NPM-ALK oncogenic signaling promotes cellular apoptosis and drug dependency

    Article • Oncogene, December 2015, Nature

    Dr Suzanne D Turner

  9. ID: 263

    Article • Cytokine, November 2015, Elsevier

    Dr Suzanne D Turner, David Levy

  10. Erratum: STAT3 regulated ARF expression suppresses prostate cancer metastasis

    Article • Nature Communications, October 2015, Nature

    Dr Suzanne D Turner

  11. Abstract 2920: Excess of cytoplasmic NPM-ALK driven oncogenic signaling is toxic and promotes cellular apoptosis and drug dependency

    Article • Cancer Research, August 2015, American Association for Cancer Research (AACR)

    Dr Suzanne D Turner

  12. STAT3 regulated ARF expression suppresses prostate cancer metastasis

    Article • Nature Communications, July 2015, Nature

    Dr Suzanne D Turner, David Levy

  13. Oncogenic role of miR ‐155 in anaplastic large cell lymphoma lacking the t(2;5) translocation

    Article • The Journal of Pathology, April 2015, Wiley

    Dr Suzanne D Turner

  14. Twenty years of modelling NPM-ALK-induced lymphomagenesis

    Article • January 2015, Frontiers in Bioscience

    Dr Suzanne D Turner

  15. Twenty years of modelling NPM-ALK-induced lymphomagenesis

    Article • January 2015, Frontiers in Bioscience

    Dr Suzanne D Turner

  16. ALCL and breast implants

    Article • Mutation Research/Reviews in Mutation Research, October 2014, Elsevier

    Dr Suzanne D Turner

  17. Anaplastic large cell lymphoma-propagating cells are detectable by side population analysis and possess an expression profile reflective of a primitive origin

    Article • Oncogene, May 2014, Nature

    Dr Suzanne D Turner

  18. Malignant Transformation of CD4+ T Lymphocytes Mediated by Oncogenic Kinase NPM/ALK Recapitulates IL-2-Induced Cell Signaling and Gene Expression Reprogramming

    Article • The Journal of Immunology, November 2013, The American Association of Immunologists

    Dr Suzanne D Turner

  19. PDGFR blockade is a rational and effective therapy for NPM-ALK–driven lymphomas

    Article • Nature Reports Stem Cells, October 2012, Springer Science + Business Media

    Dr Suzanne D Turner

  20. Anaplastic large cell lymphoma: the current state of play from a European prospective as presented at the second annual meeting of the European Research Initiative on ALCL, 27–28 June 2011

    Article • Leukemia, December 2011, Nature

    Dr Suzanne D Turner

  21. Assessment of the transforming potential of novel anaplastic lymphoma kinase point mutants

    Article • Molecular Carcinogenesis, November 2011, Wiley

    Dr Suzanne D Turner

  22. Oncogenic tyrosine kinase NPM-ALK induces expression of the growth-promoting receptor ICOS

    Article • Blood, July 2011, American Society of Hematology

    Dr Suzanne D Turner

  23. Determining the contribution of NPM1 heterozygosity to NPM-ALK-induced lymphomagenesis

    Article • Laboratory Investigation, June 2011, Nature

    Dr Suzanne D Turner

  24. The lymphoma-associated NPM-ALK oncogene elicits a p16INK4a/pRb-dependent tumor-suppressive pathway

    Article • Blood, April 2011, American Society of Hematology

    Dr Suzanne D Turner

  25. Aberrant Anaplastic Lymphoma Kinase Activity Induces a p53 and Rb-Dependent Senescence-Like Arrest in the Absence of Detectable p53 Stabilization

    Article • PLoS ONE, March 2011, PLOS

    Dr Suzanne D Turner

  26. Jailbreak: Oncogene-induced senescence and its evasion

    Article • Cellular Signalling, January 2011, Elsevier

    Dr Suzanne D Turner

  27. Identification of differential and functionally active miRNAs in both anaplastic lymphoma kinase (ALK) + and ALK − anaplastic large-cell lymphoma

    Article • Proceedings of the National Academy of Sciences, August 2010, Proceedings of the National Academy of Sciences

    Dr Suzanne D Turner

  28. Genomic profiling of pediatric ALK-positive anaplastic large cell lymphoma: A Children's Cancer and Leukaemia Group Study

    Article • Genes Chromosomes and Cancer, November 2009, Wiley

    Dr Suzanne D Turner

  29. NPM-ALK inhibits the p53 tumor suppressor pathway in an MDM2 and JNK-dependent manner

    Article • Blood, March 2009, American Society of Hematology

    Dr Suzanne D Turner

  30. NPM-ALK modulates the p53 tumour suppressor pathway in a JNK and PI 3-Kinase dependent manner: MDM-2 is a potential therapeutic target for the treatment of ALK-expressing malignancies

    Article • European Journal of Cancer Supplements, July 2008, Elsevier

    Dr Suzanne D Turner

  31. The NPM-ALK tyrosine kinase mimics TCR signalling pathways, inducing NFAT and AP-1 by RAS-dependent mechanisms

    Article • Cellular Signalling, April 2007, Elsevier

    Dr Suzanne D Turner

  32. What have we learnt from mouse models of NPM-ALK-induced lymphomagenesis?

    Article • Leukemia, May 2005, Nature

    Dr Suzanne D Turner

  33. Vav-promoter regulated oncogenic fusion protein NPM-ALK in transgenic mice causes B-cell lymphomas with hyperactive Jun kinase

    Article • Oncogene, October 2003, Nature

    Dr Suzanne D Turner

  34. Signal Transduction Pathways Mediated by the Nucleophosmin-Anaplastic Lymphoma Kinase

    Article • Biochemical Society Transactions, October 2001, Portland Press Ltd.

    Dr Suzanne D Turner

  35. Assays to predict the genotoxicity of the chromosomal mutagen etoposide — focussing on the best assay

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, June 2001, Elsevier

    Dr Suzanne D Turner

  36. The effects of dose, route of administration, drug scheduling and MDR-1 gene transfer on the genotoxicity of etoposide in bone marrow

    Article • Leukemia, October 2000, Nature

    Dr Suzanne D Turner

  37. Genotoxicity studies on the azo dye Direct Red 2 using the in vivo mouse bone marrow micronucleus test

    Article • Mutation Research/Genetic Toxicology and Environmental Mutagenesis, July 1999, Elsevier

    Dr Suzanne D Turner